Results 151 to 160 of about 82,921 (179)
Some of the next articles are maybe not open access.
Pediatric Blood & Cancer, 2021
AbstractBackgroundPEG‐asparaginase is critical in pediatric acute lymphoblastic leukemia (ALL) therapy but is highly immunogenic. Severe allergic reactions lead to substitution of further PEG‐asparaginase with Erwinia. Erwinia is associated with more frequent dosing, increased expense, and limited availability.
Meghan McCormick +3 more
openaire +3 more sources
AbstractBackgroundPEG‐asparaginase is critical in pediatric acute lymphoblastic leukemia (ALL) therapy but is highly immunogenic. Severe allergic reactions lead to substitution of further PEG‐asparaginase with Erwinia. Erwinia is associated with more frequent dosing, increased expense, and limited availability.
Meghan McCormick +3 more
openaire +3 more sources
From the Children’s Oncology Group: Evidence-Based Recommendations for PEG-Asparaginase Nurse Monitoring, Hypersensitivity Reaction Management, and Patient/Family Education [PDF]
Journal of Pediatric Oncology Nursing, 2017 PEG-aspariginase is a backbone chemotherapy agent in pediatric acute lymphoblastic leukemia and in some non-Hodgkin lymphoma therapies. Nurses lack standardized guidelines for monitoring patients receiving PEG-asparaginase and for educating patients ...
Emily Browne
exaly +2 more sources
Leukemia & Lymphoma, 2022
PEG-asparaginase is a key component in treatment regimens for acute lymphoblastic leukemia (ALL). Major side effects include thrombosis and bleeding; however, there is currently no consensus on methods to prevent these complications. In this multi-center retrospective cohort study of 101 adults, we compared two prophylaxis strategies: cryoprecipitate ...
YeeAnn Chen +10 more
openaire +2 more sources
PEG-asparaginase is a key component in treatment regimens for acute lymphoblastic leukemia (ALL). Major side effects include thrombosis and bleeding; however, there is currently no consensus on methods to prevent these complications. In this multi-center retrospective cohort study of 101 adults, we compared two prophylaxis strategies: cryoprecipitate ...
YeeAnn Chen +10 more
openaire +2 more sources
Intravenous PEG Asparaginase during Remission Induction for Childhood ALL.
Blood, 2006Abstract BACKGROUND: E.coli L-asparaginase (E.coli-ASP) is an important component of multiagent chemotherapy for childhood ALL, but is associated with multiple toxicities, including allergy in 25–30% of patients. Pegaspargase (PEG), the polyethylene glycol conjugate of E.coli ASP, has a longer circulating half-life and potentially ...
Lewis B. Silverman +5 more
openaire +1 more source
Journal of Pediatric Hematology/Oncology, 2013
Polyethylene-glycolated (PEG)-asparaginase (PEG-ASP) is a crucial component of pediatric acute lymphoblastic leukemia therapy. Although hypersensitivity reactions to PEG-ASP occur less frequently than with other formulations, they are not uncommon and have an adverse impact on patient outcomes. Intravenous (IV) administration of PEG-ASP reduces patient
Keith J, August +3 more
openaire +2 more sources
Polyethylene-glycolated (PEG)-asparaginase (PEG-ASP) is a crucial component of pediatric acute lymphoblastic leukemia therapy. Although hypersensitivity reactions to PEG-ASP occur less frequently than with other formulations, they are not uncommon and have an adverse impact on patient outcomes. Intravenous (IV) administration of PEG-ASP reduces patient
Keith J, August +3 more
openaire +2 more sources
773: PEG-ASPARAGINASE: WHAT ELSE IS NEW?
Critical Care Medicine, 2023Huma Butta, Shefali Aggarwal
openaire +1 more source
ALLERGIC REACTION TO PEG ASPARAGINASE WITH SUCCESSFUL DESENSITIZATION
Annals of Allergy, Asthma & Immunology, 2023M. Beaudoin, K. Brar, G. Robbins
openaire +1 more source
Leukemia & Lymphoma, 2017
Asparaginase is commonly de-emphasized/omitted in adult acute lymphoblastic leukemia regimens due to poor tolerability, including hepatotoxicity (HTX). Adult patients (n = 100) given induction therapy containing pegylated asparaginase (PEG) from January 2008 to February 2016 were evaluated for HTX.
Caitlin R, Rausch +6 more
openaire +2 more sources
Asparaginase is commonly de-emphasized/omitted in adult acute lymphoblastic leukemia regimens due to poor tolerability, including hepatotoxicity (HTX). Adult patients (n = 100) given induction therapy containing pegylated asparaginase (PEG) from January 2008 to February 2016 were evaluated for HTX.
Caitlin R, Rausch +6 more
openaire +2 more sources
Peg- Asparaginase induced hepatic injury-A concern for hepatologist
Journal of Clinical and Experimental Hepatology, 2022Hozefa Runderawala +5 more
openaire +1 more source
Inadvertent Intrathecal Injection of PEG-asparaginase
Journal of Pediatric Hematology/Oncology, 2010Naqvi, Ahmed, Fadoo, Zehra
openaire +1 more source